POSTKARDİYAK ARREST METABOLİK YÖNETİM

References (1)

1. Leander G, Eliasson E, Handerger H, et al. Beta lactam antibiotics and the question of dose regimen for severe infection.Prolonged infusion theroretically appealing—yet no evidence of clinical benefit. Lakartidningen 2015 (24):112. 2-Lipman J, Brett SJ, De Waele JJ, et al. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotics infusion in critically ill patients with sepsis: BLING III. Crit Care Resusc 2019 Mar;21(1):63-68. 3-Williams P, Cotta MO, Roberts JA. Pharmacokinetics/Pharmacodynamics of β-Lactams and Therapeutic Drug Monitoring: From Theory to Practical Issues in the Intensive Care Unit.Semin Respir Crit Care Med 2019 Aug;40(4):476-487. 4- Rizk NA, Kanafani ZA, Tabaja HZ, et al. Extenden infusion of beta-lactam antibiotics:optimizing therapy in critically-ill patients in the era of amtimicrobial resistance. Expert Rev Anti Infect Ther 2017 Jul;15(7):645-652. 5- Richter DC,Heininger A,Brenner T, et al. Bacterial sepsis: Diagnostics and calculated antibiotic therapy. Anaesthesist 2017 Oct;66(10):737-761.